First human test of potential new treatment for hardening skin disease
NCT ID NCT07159009
Summary
This is an early safety study testing a new drug called GB261 in people with systemic sclerosis, a condition that causes skin and organ hardening. The study will enroll 10 adults who have had the disease for 7 years or less and haven't responded well to other treatments. Researchers will primarily monitor for side effects while also checking if the drug shows any signs of helping control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.